The ascendancy of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the early sales data were astounding, the exclusivity has expired, leading to a flood of copycat alternatives that are chipping away at earnings. In addition, the industry is facing website challenges related to population trends and sh